Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies

被引：0
|
作者：
Zhitao Ying
Ting He
Xiaopei Wang
Wen Zheng
Ningjing Lin
Meifeng Tu
Yan Xie
Lingyan Ping
Chen Zhang
Weiping Liu
Lijuan Deng
Meng Wu
Feier Feng
Xin Leng
Tingting Du
Feifei Qi
Xuelian Hu
Yanping Ding
Xin-an Lu
Yuqin Song
Jun Zhu
机构：
[1] Peking University Cancer Hospital & Institute,Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing)
[2] Beijing Immunochina Pharmaceuticals Co.,undefined
[3] Ltd.,undefined
来源：
BMC Cancer | / 21卷
关键词：
CAR-T; Biodistribution; B-ALL; B-NHL; Blood;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
    Ying, Zhitao
    He, Ting
    Wang, Xiaopei
    Zheng, Wen
    Lin, Ningjing
    Tu, Meifeng
    Xie, Yan
    Ping, Lingyan
    Zhang, Chen
    Liu, Weiping
    Deng, Lijuan
    Wu, Meng
    Feng, Feier
    Leng, Xin
    Du, Tingting
    Qi, Feifei
    Hu, Xuelian
    Ding, Yanping
    Lu, Xin-an
    Song, Yuqin
    Zhu, Jun
    BMC CANCER, 2021, 21 (01)
  • [2] Chimeric antigen receptor-modified T cells: CD19 and the road beyond
    Salter, Alexander I.
    Pont, Margot J.
    Riddell, Stanley R.
    BLOOD, 2018, 131 (24) : 2621 - 2629
  • [3] CD19-Targeted Chimeric Antigen Receptor-Modified T-Cell Immunotherapy for B-Cell Malignancies
    Turtle, C. J.
    Riddell, S. R.
    Maloney, D. G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (03) : 252 - 258
  • [4] Preclinical safety evaluation of chimeric antigen receptor-modified T cells against CD19 in NSG mice
    Wen, Hairuo
    Qu, Zhe
    Yan, Yujing
    Pu, Chengfei
    Wang, Chao
    Jiang, Hua
    Hou, Tiantian
    Huo, Yan
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (23)
  • [5] Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies
    Hay, Kevin A.
    Turtle, Cameron J.
    DRUGS, 2017, 77 (03) : 237 - 245
  • [6] Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies
    Kevin A. Hay
    Cameron J. Turtle
    Drugs, 2017, 77 : 237 - 245
  • [7] Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis
    Zhang, Tengfei
    Cao, Ling
    Xie, Jing
    Shi, Ni
    Zhang, Zhen
    Luo, Zhenzhen
    Yue, Dongli
    Zhang, Zimeng
    Wang, Liping
    Han, Weidong
    Xu, Zhongwei
    Chen, Hu
    Zhang, Yi
    ONCOTARGET, 2015, 6 (32) : 33961 - 33971
  • [8] Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials
    Zhu, Yangmin
    Tan, Youping
    Ou, Ruiming
    Zhong, Qi
    Zheng, Liling
    Du, Yuanyuan
    Zhang, Qing
    Huang, Jing
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 96 (04) : 389 - 396
  • [9] Therapy of B Cell Malignancies with CD19-Specific Chimeric Antigen Receptor-Modified T Cells of Defined Subset Composition
    Turtle, Cameron J.
    Sommermeyer, Daniel
    Berger, Carolina
    Hudecek, Michael
    Shank, David M.
    Steevens, Natalia N.
    Budiarto, Tanya M.
    Karimi, Mandana
    Chaney, Colette N.
    DeVito, Anna Marie
    Heimfeld, Shelly
    Jensen, Michael C.
    Riddell, Stanley R.
    Maloney, David G.
    BLOOD, 2014, 124 (21)
  • [10] Chimeric antigen receptor-modified T cells directed against CD19 in patients with relapsed or refractory CD19-positive B-cell lymphomas: interim analysis of a phase 1 study
    Ying, Zhitao
    Xiang, Xiaoyu
    Song, Yuqin
    Ding, Ning
    Lin, Yufu
    Zheng, Wen
    Wang, Xiaopei
    Lin, Ningjing
    Tu, Meifeng
    Xie, Yan
    Zhang, Chen
    Liu, Weiping
    Deng, Lijuan
    Liu, Yanling
    Yue, Yunqiang
    Yu, Xueyun
    Liu, Hanzhi
    Duan, Panpan
    Mamuti, Mierzhati
    Guo, Xiaokai
    Chen, Feng
    Wu, Xiaoyan
    Zhang, Junqing
    Zhang, Tingting
    Huang, Xue F.
    Jones, Lindsey
    Kang, Xi
    Chen, Si-Yi
    Zhu, Jun
    LANCET ONCOLOGY, 2017, 18 : S9 - S9
12345